Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 50.5 EUR 0.2% Market Closed
Market Cap: 10.4B EUR
Have any thoughts about
Recordati Industria Chimica e Farmaceutica SpA?
Write Note

Recordati Industria Chimica e Farmaceutica SpA
Investor Relations

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs.

Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Robert Koremans M.D.
CEO & Director
No Bio Available
Mr. Luigi Felice La Corte
Group CFO & Executive Director
No Bio Available
Ms. Cathrin Petty
Executive Director
No Bio Available
Ms. Eugenia Litz
VP & Head of Investor Relations
No Bio Available
Ms. Bibianne Bon
Group Chief Legal Officer
No Bio Available
Ms. Laura Conti
Group Communications Director
No Bio Available
Mr. Gabriele Finzi
Executive VP of Corporate Development, Licensing & Innovation
No Bio Available
Ms. Alessandra Abate
Group Chief People & Culture Officer
No Bio Available
Mr. Raffaele Sabia
Chief Medical Officer
No Bio Available
Mr. Alberto Martinez
Executive Vice President of Specialty & Primary Care Business Unit
No Bio Available

Contacts

Address
MILANO
Milan
Via M. Civitali, 1
Contacts